AI-powered
podcast player
Listen to all your favourite podcasts with AI-powered features
Prof Alistair Nichol (Dublin & Melbourne) discusses why the REMAP-CAP adaptive platform trial has chosen to investigate ivermectin, given the controversy surrounding this agent.